A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a ...

Seasonal maternal respiratory syncytial virus vaccination and nirsevimab for infants demonstrate cost-effectiveness.

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

The CDC lowered the age for the pneumonia vaccination from 65 to 50 and recommended an extra COVID shot to some people.

Shares of the vaccine maker Moderna gained traction recently due to its updates of its vaccine trials with bang up results.

US health officials have approved vaccines for respiratory syncytial virus (RSV), an infection that can be deadly for some ...

Take an at-home COVID test when you feel sick, or go to an urgent care where you can be tested for COVID, RSV, and influenza ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

Researchers at Tel Aviv University have developed an effective, inexpensive, and simple COVID-19 vaccine that can be stored ...

OneDigital Investment Advisors LLC decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 9.0% ...

Moderna (MRNA) stock has fallen 71% over the last six months. While there’s still potential for near-term revenue tailwinds ...